Share on StockTwits
 

Trinity Biotech plc (NASDAQ:TRIB)’s share price reached a new 52-week high on Monday, Analyst Ratings.Net reports. The company traded as high as $25.68 and last traded at $25.59, with a volume of 86,515 shares traded. The stock had previously closed at $24.60.

TRIB has been the subject of a number of recent research reports. Analysts at Sidoti initiated coverage on shares of Trinity Biotech plc in a research note to investors on Tuesday, November 19th. They set a “buy” rating on the stock. Separately, analysts at Zacks downgraded shares of Trinity Biotech plc from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, October 30th. They now have a $26.60 price target on the stock. Finally, analysts at Jefferson Research downgraded shares of Trinity Biotech plc from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, October 29th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $22.05.

Trinity Biotech plc has a 52 week low of $14.32 and a 52 week high of $25.68. The stock has a 50-day moving average of $24.31 and a 200-day moving average of $21.6. The company has a market cap of $562.2 million and a P/E ratio of 59.28.

Trinity Biotech plc (NASDAQ:TRIB) last released its earnings data on Thursday, October 17th. The company reported $0.21 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.21. The company had revenue of $24.10 million for the quarter, compared to the consensus estimate of $24.68 million. On average, analysts predict that Trinity Biotech plc will post $0.76 earnings per share for the current fiscal year.

Trinity Biotech plc (NASDAQ:TRIB) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.